Korean J Dermatol.
2023 Nov;61(9):575-581.
Two Cases of Mycosis Fungoides Diagnosed during Dupilumab Treatment
- Kim J
1,2 - Lee G1,2
- Shin JO1,3
- Roh DY1,2
- Kim Y1,3
- Won SH1,2
- Lee J1,3
- Shin K1,3
- Kim H1,2
- Kim BS1,2
- Kim MB1,2
- Ko HC1,3
- Affiliations
-
- 1Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- 3Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
Abstract
- Dupilumab, a human monoclonal antibody targeting the interleukin-4 receptor α, has exhibited rapid and remarkable therapeutic efficacy in numerous clinical trials focusing on moderate-to-severe atopic dermatitis and prurigo nodularis. Nonetheless, instances of mycosis fungoides have been reported in patients undergoing dupilumab treatment for atopic dermatitis. We present two cases: a 36-year-old woman and a 64-year-old man who presented to our dermatology clinic with erythematous papules and plaques. Following skin biopsy, both patients were diagnosed with chronic eczematous dermatitis with prurigo. Erythematous plaques notably increased after 9 months and 1 month of dupilumab treatment, respectively. Subsequent biopsies confirmed histopathological markers consistent with mycosis fungoides. The first patient underwent chemotherapy for lymph node metastasis, while the second received oral acitretin, narrow-band ultraviolet B, and topical corticosteroids.
